Discover perspectives on the latest findings, biggest challenges and most exciting successes in our collective work.
At P-Values, you’ll find updates, perspective, insights and information from staff and partners working on the frontlines of research, advocacy and implementation. P-value is a statistical term for the probability that a trial result is reliable and not the outcome of chance.
Blog Post
This week the Global Fund and Gilead announced next steps in the process to rollout injectable lenacapavir, the new UNAIDS Global AIDS Update was released, and South Africa saw a partial reprieve for NIH-funded research. We also track AVAC’s court case against the foreign aid freeze and Congressional advocacy to protect NIH funding.
Blog Post
This year’s IAS Conference comes at a defining moment. Dramatic scientific advances are within reach, but global funding cuts are placing these innovations at risk. All this is jeopardizing the gains that communities, advocates, and researchers have fought for decades to achieve. Click for more, including our roadmap highlighting sessions where prevention and the larger issues of global health equity and sustainability are in the spotlight.
Blog Post
This week we saw Congress pass the President’s US domestic policy agenda that will rob approximately 17 million Americans of access to health care in order to provide tax cuts and workarounds for the rich. We also saw the official closure of USAID; restructuring of WHO leadership amid funding shortfalls; the US Supreme Court’s ruling preserving preventive care, including PrEP, and another ruling limiting federal courts’ ability to block presidential actions.
showing 1-10 of 1109
This week the Global Fund and Gilead announced next steps in the process to rollout injectable lenacapavir, the new UNAIDS Global AIDS Update was released, and South Africa saw a partial reprieve for NIH-funded research. We also track AVAC’s court case against the foreign aid freeze and Congressional advocacy to protect NIH funding.
This year’s IAS Conference comes at a defining moment. Dramatic scientific advances are within reach, but global funding cuts are placing these innovations at risk. All this is jeopardizing the gains that communities, advocates, and researchers have fought for decades to achieve. Click for more, including our roadmap highlighting sessions where prevention and the larger issues of global health equity and sustainability are in the spotlight.
This week we saw Congress pass the President’s US domestic policy agenda that will rob approximately 17 million Americans of access to health care in order to provide tax cuts and workarounds for the rich. We also saw the official closure of USAID; restructuring of WHO leadership amid funding shortfalls; the US Supreme Court’s ruling preserving preventive care, including PrEP, and another ruling limiting federal courts’ ability to block presidential actions.
AVAC welcomes today’s ruling affirming the constitutionality of the Affordable Care Act’s preventive services mandate, including coverage for HIV pre-exposure prophylaxis (PrEP) at no cost to patients. This decision represents a critical victory for public health, health equity, and the millions of people who rely on preventive services to stay healthy and safe.
This week brought major media attention to the devastating dismantling of USAID, even as the FDA’s approval of lenacapavir for PrEP signaled new hope in HIV prevention. At the same time, vaccines were under even greater assault as the US administration announced it would withdraw support from Gavi based on spurious claims, while the CDC’s Advisory Committee on Immunization Practices met for the first time since the Secretary of Health and Human Services fired leading vaccine experts and replaced them with a group of skeptics.
It’s only been 22 weeks since the US President began dismantling US foreign aid. AVAC took a public stand against this attack on global health in our court case. All this comes at the same time as the introduction of a potentially transformational moment in HIV prevention — the introduction of injectable lenacapavir for PrEP.
Prevention Option:
This week, we cover the US FDA approval of injectable lenacapavir (LEN) for PrEP, the “most transformative prevention product we’ve had in 44 years of this epidemic”, which demands urgent action if the remarkable science is translated into public health impact. Plus, updates on South Africa’s HIV program in crisis, oversight changes on NIH’s HIV clinical guidelines, and a court ruling halting illegal grant terminations.
This is the moment for all stakeholders to build on the momentum science. LEN has moved faster through regulatory review than any prevention product to date. Now it’s up to all of us to make sure that that progress translates into real, sustained impact on the epidemic, led by communities around the world. Let’s get to work.
This week brought the unprecedented removal of the US vaccine advisory committee, layoff reversals and confusion at the US CDC and a public letter signed by over 1,000 NIH scientists denouncing the administration’s actions. And just as this week’s issue was going to press, the US House of Representatives passed the President’s request for a rescission of billions of dollars – primarily for foreign assistance. This week underscored the urgency of defending evidence-based health policy.
AVAC strongly condemns Secretary of Health and Human Services, Robert F. Kennedy, Jr., for removing all members of the Advisory Committee on Immunization Practices (ACIP). This committee of vaccine experts—with decades of experience in vaccine development, delivery and safety—is responsible for developing the country’s vaccine policies and recommendations for the CDC.
showing 1-10 of 1109
Discover perspectives on the latest findings, biggest challenges and most exciting successes in our collective work.
AVAC’s email list for organization and individuals interested in timely updates and critical perspectives on developments in biomedical HIV prevention.
A comprehensive round-up of HIV prevention media coverage and scientific publications.
Each month this podcast uses interviews, discussion and first-person reflections to explore vital topics confronting the field of HIV prevention research.
PxWire is AVAC’s quarterly update on biomedical HIV prevention. Each issue highlights key developments, challenges and opportunities, and features a centerspread infographic that provides a visual tool for framing these issues.
Pandemic Watch is a curated news digest on the latest pandemic prevention, preparedness, and response (PPPR) news and resources.
A collection of official statements from AVAC.
Media clippings featuring AVAC, its staff and close partners in the news media.